
    
      This is a prospective, single-center, randomized, controlled trial. Patients admitted with
      spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam
      1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.
    
  